Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide

Journal of Clinical Investigation

Volumn 100, Issue 11, 1997, Pages 2691-2696

  Buechner, Stanislaw A ^a   Wernli, Marion ^b   Harr, Thomas ^b   Hahn, Sinuhe ^b   Itin, Peter ^a   Erb, Peter ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Apoptosis; Basal cell carcinoma; CD95; CD95 ligand; IFN alpha

Indexed keywords

CD4 ANTIGEN; CELL RECEPTOR; FAS ANTIGEN; LIGAND; RECOMBINANT ALPHA2B INTERFERON;

APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER REGRESSION; CARCINOMA CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRALESIONAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0031442027     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119814     Document Type: Article

References (45)

1. Greenway, H.T., R.C. Cornell, D.J. Tanner, E. Peets, G.M. Bordin, and C. Nagi. 1986. Treatment of basal cell carcinoma with intralesional interferon. J. Am. Acad Dermatol. 15:437-443.
2. Buechner, S.A. 1991. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. J. Am. Acad. Dermatol. 24:731-734
3. Cornell, R.C., H.T. Greenway, S.B. Tucker, L. Edwards, S. Ashworth, J.C. Vance, D.J. Tanner, E.L. Tylor, K.A. Smiles, and E.A. Peets. 1990. Intralesional interferon therapy for basal cell carcinoma. J. Am. Acad. Dermatol. 23: 694-700.
4. Wickramasinghe, L., T.C. Hindson, and H. Wacks. 1989 Treatment of neoplastic skin lesions with intralesional interferon. J. Am. Acad. Dermatol. 20. 71-74.
5. Bottomley, W.W., and K. Keczkes. 1991. Treatment of basal cell carcinomas with intralesional recombinant interferon-alfa-2b. J. Dermatol. Treat. 2:15-16
6. Thestrup-Pedersen, K., I.E. Jacobsen, and G. Frentz. 1990. Intralesional interferon-alpha 2b treatment of basal cell carcinoma. Acta Dermato-Venereol. 70:512-514.
7. Grob, J.J., A.M. Collet, M.H. Munoz, and J.J. Bonerandi. 1988. Treatment of large basal cell carcinomas with intralesional interferon alpha-2a. Lancet. 1:878-879.
8. Buechner, S.A., S. Lautenschlager, P. Schiller, P. Itin, P. Bigliardi, J. Izakovic, B. Yilmaz, D. Müller, and S. Courvoisier. 1995 Treatment of basal cell carcinomas with intralesional interferon alfa-2b. Dermatology (Basel) 191:173-174.
9. Hunt, M.J., G.M. Halliday, D. Weedon, B.E. Cooke, and R.S. Barnetson. 1994. Regression in basal cell carcinoma: an immunohistochemical analysis. Br. J. Dermatol. 130:1-8.
10. Chimenti, S., K. Peris, S. Di Cristofaro, M.C. Fargnoli, and G. Torlone. 1995. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma Dermatologv (Basel). 190:214-217.
11. Gresser, I. 1990. Biologic effects of interferons. J. Investig. Dermatol. 95: 66S-71S.
12. Ucar, R., M. Sanwo, K. Ucar, and G. Beall. 1995. Interferons: their role in clinical practice. Ann. Allergy. 75:377-386.
13. Knop, J. 1990. Immunologic effects of interferon. J. Investig. Dermatol. 95;72S-74S.
14. Mozzanica, N., A. Cattaneo, V. Boneschi, L. Brambilla, E. Melotti, and A.F. Finzi. 1990. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha-2-interteron. Arch. Dermatol. Res. 282:311-317.
15. Williams, G.T. 1994. Apoptosis in the immune system. J. Pathol. 173:1-4.
16. Ueda, N., and S.V. Shah. 1994. Apoptosis. J. Lab. Clin. Med. 124:169-177.
17. Golstein, P., D.M. Ojcius, and J.D.E. Young. 1991. Cell death mechanisms and the immune system. Immunol. Rev. 121:29-65.
18. Wyllie, A.H., J.F.R. Kerr, and A.R. Currie. 1980. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68:251-306.
19. Buja, L.M., M.L. Eigenbrodt, and E.H. Eigenbrodt. 1993. Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch. Pathol. Lab. Med. 117:1208-1214.
20. Kerr, J.F.R., C.M. Winterford, and B.V. Harmon. 1994. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:2013-2026.
21. Stalder, T., S.H. Hahn, and P. Erb. 1994. Fas antigen is the major target molecule for CD4+ T-cell-mediated cytotoxicity. J. Immunol. 152:1127-1133.
22. Hanabuchi, S., M. Koyanagi, A. Kawasaki, N. Shinohara, A. Matsuzawa, Y. Nishimura, Y. Kobayashi, S. Yonehara., H. Yagita, and K. Okumura. 1994. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. USA. 91:4930-4934.
23. Ju, S.T., H.L. Cui, D.J. Panka, R. Ettinger, and A. Marshakrothstein. 1994. Participation of target Fas protein in apoptosis pathway induced by CD4(+) Th1 and CD8(+) cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 91: 4185-4189.
24. Hahn, S., R. Gehri, and P. Erb. 1995. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 146:57-79.
25. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science. 267: 1449-1456.
26. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO (Eur. Mol. Biol. Organ) J. 14:1129-1135.
27. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:271-279.
28. Gavrieli, Y., Y. Sherman, and S. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501.
29. Thompson, C.B. 1995. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456-1462.
30. Leithäuser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Brüderlein, C. Henne, A. Schmidt, K.M. Debatin, P.H. Krammer, and P. Möller. 1993. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69:415-429.
31. Oishi, M., K. Maeda, and S. Sugiyama. 1994. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte squamous cell carcinoma cell lines. Arch. Dermatol. Res. 286:396-407.
32. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377: 630-632.
33. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
34. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, et al. 1996. Fas ligand in human serum. Nat. Med. 2:317-322.
35. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-1082.
36. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implication for tumor immune escape. Science. 274:1363-1366.
37. Strand, S., W.J. Hofmann, H. Hug, M. Müller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion. Nat. Med. 2:1361-1366.
38. Saas, P., P.R. Walker, M. Hahne, A.L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E.G. VanMeir, N. Detribolet., J. Tschopp., and P.Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99:1173-1178.
39. Friesen, C., I. Herr, P.H. Krammer, and K.M. Debatin. 1996. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-577.
40. Lenardo, M.J. 1996. Fas and the art of lymphocyte maintenance. J. Exp. Med. 183:721-724.
41. Rodriguez-Villanueva, J., and T.J. McDonnell. 1995. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int. J. Cancer. 61:110-114.
42. Brinkmann, V., T. Geiger., S. Alkan, and C.H. Heusser. 1993. Interferon-alpha increases the frequency of interferon-gamma-producing human CD4+ T-cells. J. Exp. Med 178:1655-1663.
43. Tong, Y., and S.B. Tucker. 1993. Normal skin lymphocytic and Langerhans' cell responses to intradermal interferon alpha-2b injections. Am. J. Med. Sci. 306:23-27.
44. Sayama, K., S. Yonehara, Y. Watanabe, and Y. Miki. 1994. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J. Investig. Dermatol. 103:330-334.
45. Takahashi, H., H. Kobayashi, Y. Hashimoto, S. Matsuo, and H. Iizuka. 1995. Interferon-gamma-dependent stimulation of Fas antigen in SV40-transformed human keratinocytes: modulation of the apoptotic process by protein kinase C. J. Investig. Dermatol. 105:810-815.